Rituximab Biosimilars Global Market Report 2024

Description

A rituximab biosimilar is a chimeric monoclonal antibody designed to target the B cell-specific protein CD20 within the immune system. This monoclonal antibody, rituximab, is effective in eliminating B cells, making it a valuable treatment for conditions characterized by an excess, overactive, or otherwise abnormal presence of B cells.

Rituximab biosimilars can be administered through various routes, including subcutaneous, intravenous, and molecular methods. Intravenous therapy involves the direct delivery of fluids, medications, and nutrients into a patient's vein. The applications of rituximab biosimilars span across medical conditions such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others. These biosimilars are distributed through different channels, including hospital pharmacies, online pharmacies, retail pharmacies, and various direct distribution channels.

The rituximab biosimilars market research report is one of a series of new reports from The Business Research Company that provides rituximab biosimilars market statistics, including rituximab biosimilars industry global market sizes, regional shares, competitors with a rituximab biosimilars market share, detailed rituximab biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the rituximab biosimilars industry. This rituximab biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rituximab biosimilars market size has grown rapidly in recent years. It will grow from $2.66 billion in 2023 to $3.02 billion in 2024 at a compound annual growth rate (CAGR) of 13.3%. The expansion observed in the historical period can be ascribed to government initiatives, heightened healthcare spending, growth in research and development expenditure for biopharmaceuticals, the cost-effectiveness of biosimilars, and the burgeoning growth in emerging markets.

The rituximab biosimilars market size is expected to see rapid growth in the next few years. It will grow to $4.89 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. The anticipated growth in the forecast period can be linked to the aging population, improved access to healthcare, and an increasing prevalence of chronic diseases. Noteworthy trends during this period involve capitalizing on updated FDA regulations for the development of biosimilar drugs, forging strategic partnerships and collaboration agreements with major players to broaden research and development initiatives for new drug developments, and making substantial investments in research and development activities to create effective and innovative biosimilars.

The increasing incidence of non-Hodgkin's lymphoma (NHL) is anticipated to contribute to the expansion of the rituximab biosimilars market. Non-Hodgkin's lymphoma, or lymphoma, is a form of cancer that originates in white blood cells and lymphocytes, integral components of the body's immune system. According to the American Cancer Society, NHL ranks as the most prevalent cancer in the USA, constituting approximately 4% of all cancers. In the United States, an estimated 81,560 individuals (45,630 men and 35,930 women) were expected to receive a NHL diagnosis in 2021. Consequently, the increasing instances of non-Hodgkin's lymphoma are projected to result in a heightened demand for rituximab biosimilars throughout the forecast period.

The upsurge in the prevalence of autoimmune diseases is poised to drive the growth of the rituximab biosimilars market in the future. Autoimmune diseases encompass disorders wherein the body's immune system attacks healthy tissues under the misconception that they are foreign. Rituximab biosimilars find application in treating autoimmune diseases by targeting specific B cells, thereby mitigating inflammation and autoimmune responses. For example, as of July 2021, the Cleveland Clinic reported that in the United States, 1.4 million people are affected by Crohn's disease or ulcerative colitis, and one million are diagnosed with lupus. Moreover, autoimmune diseases rank among the top 10 causes of death for women across all age groups up to 64. Hence, the surge in autoimmune diseases' prevalence is a significant driver of the rituximab biosimilars market's growth.

Companies in the biosimilars industry continue to prioritize new product development through collaborations with industry peers. This trend is particularly evident in the rituximab biosimilars market. An example of such collaboration occurred in July 2023 when Dr. Reddy's Laboratories partnered with Fresenius Kabi to commercialize their proposed rituximab biosimilar in the US. The goal of this collaboration is to introduce a more affordable and accessible biosimilar version of rituximab to the market, offering an alternative treatment option for patients. The introduction of a biosimilar rituximab in the United States has the potential to enhance access to this crucial treatment for various conditions, including rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis, and microscopic polyangiitis.

Key players in the rituximab biosimilars market are actively engaged in the development of FDA-approved rituximab biosimilars to establish a competitive advantage. A rituximab biosimilar that receives FDA approval is used in the treatment of specific immune-related conditions and malignancies. For instance, in June 2022, the US-based biopharmaceutical company Amgen Inc. obtained FDA approval for RIABNI (rituximab-arrx), a biosimilar to Rituxan (rituximab). RIABNI is the only FDA-approved rituximab biosimilar for all available Rituxan indications, encompassing Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), Microscopic Polyangiitis (MPA), and moderately to severely active rheumatoid arthritis (RA) with an inadequate response to TNF antagonist therapies.

Major companies operating in the rituximab biosimilars market report are Cellitron, Novartis AG, Pfizer, BIOCAD, Shanghai Henlius Biotech Inc., Sandoz, Innovent Biologics Inc., Sinocelltech, Cadila Pharmaceuticals, Hetero Drugs Limited, Dr. Reddy's Laboratories, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Reliance Life Sciences India, Zenotech Laboratories, NAPP Pharmaceuticals Limited, Mundipharma Deutschland GmbH & Co. KG, Celltrion, Biocad, MABION S.A., Janssen Pharmaceutical, Amgen, Teva Pharmaceuticals, Celltrion Healthcare, Coherus BioSciences, Innovent Biologics, Mylan, Aryogen Biopharma, TR-Pharm, Hikma Pharmaceuticals plc.

North America was the largest region in the rituximab biosimilars market in 2023. Middle East is expected to be the fastest-growing region in the rituximab biosimilars market report during the forecast period. The regions covered in the rituximab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the rituximab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The rituximab biosimilar market consists of sales of mabthera, truxima, ruxience, or rixathon. Values in this market are ''factory gate values,'' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rituximab Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rituximab biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rituximab biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rituximab biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Route Of Administration: Subcutaneous; Intravenous; Molecular Type
2) By Application: Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Rheumatoid Arthritis; Other Applications
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Mail Order
Companies Mentioned: Cellitron; Novartis AG; Pfizer; BIOCAD; Shanghai Henlius Biotech Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r14596

1. Executive Summary

2. Rituximab Biosimilars Market Characteristics

3. Rituximab Biosimilars Market Trends And Strategies

4. Rituximab Biosimilars Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Rituximab Biosimilars Market Size and Growth

5.1. Global Rituximab Biosimilars Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Rituximab Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Rituximab Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Rituximab Biosimilars Market Segmentation

6.1. Global Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Subcutaneous
Intravenous
Molecular Type
6.2. Global Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Non-Hodgkin's Lymphoma
Chronic Lymhocytic Leukemia
Rheumatoid Arthritis
Other Applications
6.3. Global Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Other Direct Distribution Channels

7. Rituximab Biosimilars Market Regional And Country Analysis

7.1. Global Rituximab Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Rituximab Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Rituximab Biosimilars Market

8.1. Asia-Pacific Rituximab Biosimilars Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Rituximab Biosimilars Market

9.1. China Rituximab Biosimilars Market Overview
9.2. China Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Rituximab Biosimilars Market

10.1. India Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Rituximab Biosimilars Market

11.1. Japan Rituximab Biosimilars Market Overview
11.2. Japan Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Rituximab Biosimilars Market

12.1. Australia Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Rituximab Biosimilars Market

13.1. Indonesia Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Rituximab Biosimilars Market

14.1. South Korea Rituximab Biosimilars Market Overview
14.2. South Korea Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Rituximab Biosimilars Market

15.1. Western Europe Rituximab Biosimilars Market Overview
15.2. Western Europe Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Rituximab Biosimilars Market

16.1. UK Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Rituximab Biosimilars Market

17.1. Germany Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Rituximab Biosimilars Market

18.1. France Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Rituximab Biosimilars Market

19.1. Italy Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Rituximab Biosimilars Market

20.1. Spain Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Rituximab Biosimilars Market

21.1. Eastern Europe Rituximab Biosimilars Market Overview
21.2. Eastern Europe Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Rituximab Biosimilars Market

22.1. Russia Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Rituximab Biosimilars Market

23.1. North America Rituximab Biosimilars Market Overview
23.2. North America Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Rituximab Biosimilars Market

24.1. USA Rituximab Biosimilars Market Overview
24.2. USA Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Rituximab Biosimilars Market

25.1. Canada Rituximab Biosimilars Market Overview
25.2. Canada Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Rituximab Biosimilars Market

26.1. South America Rituximab Biosimilars Market Overview
26.2. South America Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Rituximab Biosimilars Market

27.1. Brazil Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Rituximab Biosimilars Market

28.1. Middle East Rituximab Biosimilars Market Overview
28.2. Middle East Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Rituximab Biosimilars Market

29.1. Africa Rituximab Biosimilars Market Overview
29.2. Africa Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Rituximab Biosimilars Market Competitive Landscape And Company Profiles

30.1. Rituximab Biosimilars Market Competitive Landscape
30.2. Rituximab Biosimilars Market Company Profiles
- 30.2.1. Cellitron
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Novartis AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Pfizer
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. BIOCAD
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Shanghai Henlius Biotech Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Rituximab Biosimilars Market Other Major And Innovative Companies

31.1. Sandoz
31.2. Innovent Biologics Inc.
31.3. Sinocelltech
31.4. Cadila Pharmaceuticals
31.5. Hetero Drugs Limited
31.6. Dr. Reddy's Laboratories
31.7. Shanghai Fosun Pharmaceutical (Group) Co. Ltd.
31.8. Reliance Life Sciences India
31.9. Zenotech Laboratories
31.10. NAPP Pharmaceuticals Limited
31.11. Mundipharma Deutschland GmbH & Co. KG
31.12. Celltrion
31.13. Biocad
31.14. MABION S.A.
31.15. Janssen Pharmaceutical

32. Global Rituximab Biosimilars Market Competitive Benchmarking

33. Global Rituximab Biosimilars Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Rituximab Biosimilars Market

35. Rituximab Biosimilars Market Future Outlook and Potential Analysis

35.1 Rituximab Biosimilars Market In 2028 - Countries Offering Most New Opportunities
35.2 Rituximab Biosimilars Market In 2028 - Segments Offering Most New Opportunities
35.3 Rituximab Biosimilars Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer